RRM1 and Pleural effusion: Moreover, in 2014 Szulkin et al., reported that the proportion of malignant cells and RRM1 reactivity in the pleural effusions of patients with MPM correlate to drug sensitivity and survival time, therefore analyzing RRM1 in pleural effusion might be a plausible way for determining which is the best therapy in the first-line setting [24].